Please read original press release here (pdf. file).
In summary: Agilent Technologies Inc. (NYSE: A) today announced that BGI (formerly known as Beijing Genomics Institute) has selected Agilent to streamline and enhance the throughput of BGI’s next generation sequencing workflow. BGI is the largest genome-sequencing facility in Asia and one of the largest genome research centers in the world.
BGI selected Agilent for its comprehensive portfolio of research products to address bottlenecks in the next-generation sequencing workflow. BGI will use Agilent’s SureSelect Target Enrichment System, Agilent’s Bravo Automated Liquid Handling Platform and Agilent’s 2100 Bioanalyzer in its research.
“As one of the world’s largest genome centers and sequencing facilities, we are aiming to streamline our genomics platform with minimal manual interference,” said Xiuqing Zhang, vice president of BGI. “We are excited that Agilent can meet our requirements to the greatest extent. The technology platforms supplied by Agilent will provide us with more options to better serve our collaborators doing exome sequencing.”